Back to Startup Insights
Solstice Oncology
Clinical-stage immuno-oncology company treating cancer in the neoadjuvant setting before surgery; lead asset porustobart, a second-generation Fc-enhanced CTLA-4 antibody licensed from Harbour BioMed, is in Phase 2 with pembrolizumab for MSS colon cancer.
Headquarters
Boston, USA
Year Founded
2026
Founders
Caroline J. Loew (CEO)
Country
United States
Financial Information
Funding Stage
Series A
Recent Funding
$225M
Funding By
RA Capital Management, Canaan Partners, Forbion
Core Technology
Fc-enhanced CTLA-4 antibody (porustobart) + anti-PD-1 combination
Product Type
Drug
Pipeline Stage (Very Important)
Phase II
Regulatory Status
- IND Filed: Yes
- FDA/EMA Status: FDA Clinical
- Clinical Trial Registration: Phase 2 neoadjuvant MSS colon cancer (porustobart + pembrolizumab)
- Patents / IP Status: Licensed from Harbour BioMed
Partnerships
Pharma Collaborations
Harbour BioMed
Academic / Hospital Tie-ups
Leading academic cancer centers (trial network)
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
Early neoadjuvant CTLA-4/PD-1 combo aimed at curative MSS colon cancer